Aseem Anand
Overview
Explore the profile of Aseem Anand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
2168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Probst S, Bjartell A, Anand A, Skamene T, Ferrario C
Nucl Med Mol Imaging
. 2022 Jul;
56(4):188-195.
PMID: 35846415
Background: Radium-223, an alpha-emitting therapeutic radiopharmaceutical, prolongs overall survival (OS) in patients with symptomatic bone-predominant metastatic castration-resistant prostate cancer (mCRPC). PSMA PET/CT is a molecular imaging tool for whole-body imaging...
2.
Yang T, Liu Y, Chen S, Tian J, Zhu X, Zhang L, et al.
Prostate
. 2022 Jun;
82(13):1284-1292.
PMID: 35747943
Background: To investigate the prognostic value and potential therapeutic target of the baseline serum hormones in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone. Methods: This retrospective study...
3.
Anand A, Heller G, Fox J, Danila D, Bjartell A, Edenbrandt L, et al.
Clin Genitourin Cancer
. 2022 Mar;
20(3):270-277.
PMID: 35279418
Introduction: Radiographic progression-free survival (rPFS) by Prostate Cancer Working Group (PCWG) criteria is a radiographic endpoint. The automated bone scan index (aBSI) quantifies osseous disease burden on bone scintigraphy as...
4.
Johnsson K, Brynolfsson J, Sahlstedt H, Nickols N, Rettig M, Probst S, et al.
Eur J Nucl Med Mol Imaging
. 2021 Aug;
49(3):1041-1051.
PMID: 34463809
Purpose: The application of automated image analyses could improve and facilitate standardization and consistency of quantification in [F]DCFPyL (PSMA) PET/CT scans. In the current study, we analytically validated aPROMISE, a...
5.
Nickols N, Anand A, Johnsson K, Brynolfsson J, Borreli P, Parikh N, et al.
J Nucl Med
. 2021 May;
63(2):233-239.
PMID: 34049980
Standardized staging and quantitative reporting are necessary to demonstrate the association of F-DCFPyL PET/CT imaging with clinical outcome. This work introduces an automated platform, aPROMISE, to implement and extend the...
6.
Puterman C, Bjoersdorff M, Amidi J, Anand A, Soller W, Jiborn T, et al.
Scand J Urol
. 2021 May;
55(4):293-297.
PMID: 33939583
Background: Previous studies have investigated [18F]-fluorocholine (FCH) positron emission tomography with computed tomography (PET/CT) in primary staging of men with intermediate or high-risk prostate cancer and have generally shown high...
7.
Razavi P, Li B, Brown D, Jung B, Hubbell E, Shen R, et al.
Nat Med
. 2019 Nov;
25(12):1928-1937.
PMID: 31768066
Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA (cfDNA) requires understanding of the various biological compartments contributing to the cfDNA pool. We sought to define the technical...
8.
Anand A, Tragardh E, Edenbrandt L, Beckman L, Svensson J, Thellenberg C, et al.
J Nucl Med
. 2019 Oct;
61(5):671-675.
PMID: 31586004
For effective clinical management of patients being treated with Ra, there is a need for radiographic response biomarkers to minimize disease progression and to stratify patients for subsequent treatment options....
9.
McNamara M, Oyekunle T, Chin B, Oldan J, Anand A, Ritz M, et al.
Prostate
. 2019 May;
79(10):1106-1116.
PMID: 31045266
Background: Radium-223 improves survival and time to first symptomatic skeletal event in symptomatic bone predominant metastatic castrate-resistant prostate cancer (mCRPC). The imaging response to radium-223 has not been well characterized....
10.
Armstrong A, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, et al.
JAMA Oncol
. 2018 May;
4(7):944-951.
PMID: 29799999
Importance: Prostate cancer commonly metastasizes to bone, and bone metastases are associated with pathologic fractures, pain, and reduced survival. Bone disease is routinely visualized using the technetium Tc 99m (99mTc)...